• Something wrong with this record ?

Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma

P. Kubatka, M. Kello, K. Kajo, M. Samec, A. Liskova, K. Jasek, L. Koklesova, T. Kuruc, M. Adamkov, K. Smejkal, E. Svajdlenka, P. Solar, M. Pec, D. Büsselberg, V. Sadlonova, J. Mojzis

. 2020 ; 22 (1) : . [pub] 20201226

Language English Country Switzerland

Document type Journal Article

Grant support
VEGA 1/0136/19; VEGA 1/0653/19; and 1/0753/17 Scientific Grant Agency of the Ministry of Education of the Slovak Republic
APVV-16-0021 and APVV-16-0446 Slovak Research and Development Agency
ITMS2014+: 313011V455 Open scientific community for modern interdisciplinary research in medicine (OPENMED)
NPRP 11S-1214-170101 National Priorities Research Program grant (NPRP 11S-1214-170101; awarded to Professor Dr. Dietrich Büsselberg, June 2019-Current) from the Qatar National Research Fund (QNRF, a member of Qatar Foundation).

Comprehensive scientific data provide evidence that isolated phytochemicals or whole plant foods may beneficially modify carcinogenesis. The aim of this study was to evaluate the oncostatic activities of Rhus coriaria L. (sumac) using animal models (rat and mouse), and cell lines of breast carcinoma. R. coriaria (as a powder) was administered through the diet at two concentrations (low dose: 0.1% (w/w) and high dose: 1 % (w/w)) for the duration of the experiment in a syngeneic 4T1 mouse and chemically-induced rat mammary carcinoma models. After autopsy, histopathological and molecular analyses of tumor samples in rodents were performed. Moreover, in vitro analyses using MCF-7 and MDA-MB-231 cells were conducted. The dominant metabolites present in tested R. coriaria methanolic extract were glycosides of gallic acid (possible gallotannins). In the mouse model, R. coriaria at a higher dose (1%) significantly decreased tumor volume by 27% when compared to controls. In addition, treated tumors showed significant dose-dependent decrease in mitotic activity index by 36.5% and 51% in comparison with the control group. In the chemoprevention study using rats, R. coriaria at a higher dose significantly reduced the tumor incidence by 20% and in lower dose non-significantly reduced tumor frequency by 29% when compared to controls. Evaluations of the mechanism of oncostatic action using valid clinical markers demonstrated several positive alterations in rat tumor cells after the treatment with R. coriaria. In this regard, histopathological analysis of treated tumor specimens showed robust dose-dependent decrease in the ratio of high-/low-grade carcinomas by 66% and 73% compared to controls. In treated rat carcinomas, we found significant caspase-3, Bax, and Bax/Bcl-2 expression increases; on the other side, a significant down-regulation of Bcl-2, Ki67, CD24, ALDH1, and EpCam expressions and MDA levels. When compared to control specimens, evaluation of epigenetic alterations in rat tumor cells in vivo showed significant dose-dependent decrease in lysine methylation status of H3K4m3 and H3K9m3 and dose-dependent increase in lysine acetylation in H4K16ac levels (H4K20m3 was not changed) in treated groups. However, only in lower dose of sumac were significant decreases in the expression of oncogenic miR210 and increase of tumor-suppressive miR145 (miR21, miR22, and miR155 were not changed) observed. Finally, only in lower sumac dose, significant decreases in methylation status of three out of five gene promoters-ATM, PTEN, and TIMP3 (PITX2 and RASSF1 promoters were not changed). In vitro evaluations using methanolic extract of R. coriaria showed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using Resazurin, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). In conclusion, sumac demonstrated significant oncostatic activities in rodent models of breast carcinoma that were validated by mechanistic studies in vivo and in vitro.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026325
003      
CZ-PrNML
005      
20211026133004.0
007      
ta
008      
211013s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22010183 $2 doi
035    __
$a (PubMed)33375383
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia $u Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia
245    10
$a Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma / $c P. Kubatka, M. Kello, K. Kajo, M. Samec, A. Liskova, K. Jasek, L. Koklesova, T. Kuruc, M. Adamkov, K. Smejkal, E. Svajdlenka, P. Solar, M. Pec, D. Büsselberg, V. Sadlonova, J. Mojzis
520    9_
$a Comprehensive scientific data provide evidence that isolated phytochemicals or whole plant foods may beneficially modify carcinogenesis. The aim of this study was to evaluate the oncostatic activities of Rhus coriaria L. (sumac) using animal models (rat and mouse), and cell lines of breast carcinoma. R. coriaria (as a powder) was administered through the diet at two concentrations (low dose: 0.1% (w/w) and high dose: 1 % (w/w)) for the duration of the experiment in a syngeneic 4T1 mouse and chemically-induced rat mammary carcinoma models. After autopsy, histopathological and molecular analyses of tumor samples in rodents were performed. Moreover, in vitro analyses using MCF-7 and MDA-MB-231 cells were conducted. The dominant metabolites present in tested R. coriaria methanolic extract were glycosides of gallic acid (possible gallotannins). In the mouse model, R. coriaria at a higher dose (1%) significantly decreased tumor volume by 27% when compared to controls. In addition, treated tumors showed significant dose-dependent decrease in mitotic activity index by 36.5% and 51% in comparison with the control group. In the chemoprevention study using rats, R. coriaria at a higher dose significantly reduced the tumor incidence by 20% and in lower dose non-significantly reduced tumor frequency by 29% when compared to controls. Evaluations of the mechanism of oncostatic action using valid clinical markers demonstrated several positive alterations in rat tumor cells after the treatment with R. coriaria. In this regard, histopathological analysis of treated tumor specimens showed robust dose-dependent decrease in the ratio of high-/low-grade carcinomas by 66% and 73% compared to controls. In treated rat carcinomas, we found significant caspase-3, Bax, and Bax/Bcl-2 expression increases; on the other side, a significant down-regulation of Bcl-2, Ki67, CD24, ALDH1, and EpCam expressions and MDA levels. When compared to control specimens, evaluation of epigenetic alterations in rat tumor cells in vivo showed significant dose-dependent decrease in lysine methylation status of H3K4m3 and H3K9m3 and dose-dependent increase in lysine acetylation in H4K16ac levels (H4K20m3 was not changed) in treated groups. However, only in lower dose of sumac were significant decreases in the expression of oncogenic miR210 and increase of tumor-suppressive miR145 (miR21, miR22, and miR155 were not changed) observed. Finally, only in lower sumac dose, significant decreases in methylation status of three out of five gene promoters-ATM, PTEN, and TIMP3 (PITX2 and RASSF1 promoters were not changed). In vitro evaluations using methanolic extract of R. coriaria showed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using Resazurin, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). In conclusion, sumac demonstrated significant oncostatic activities in rodent models of breast carcinoma that were validated by mechanistic studies in vivo and in vitro.
650    _2
$a zvířata $7 D000818
650    _2
$a fytogenní protinádorové látky $x farmakologie $7 D000972
650    _2
$a apoptóza $7 D017209
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
650    _2
$a buněčný cyklus $7 D002453
650    _2
$a proliferace buněk $7 D049109
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši nahé $7 D008819
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a rostlinné extrakty $x farmakologie $7 D010936
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a Rhus $x chemie $7 D029045
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kello, Martin $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, 040 11 Košice, Slovakia
700    1_
$a Kajo, Karol $u Department of Pathology, St. Elisabeth Oncology Institute, 812 50 Bratislava, Slovakia $u Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia
700    1_
$a Samec, Marek $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Liskova, Alena $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Jasek, Karin $u Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia
700    1_
$a Koklesova, Lenka $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Kuruc, Tomas $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, 040 11 Košice, Slovakia
700    1_
$a Adamkov, Marian $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Smejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, 612 42 Brno, Czech Republic
700    1_
$a Svajdlenka, Emil $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, 612 42 Brno, Czech Republic
700    1_
$a Solar, Peter $u Department of Medical Biology, Faculty of Medicine, P. J. Šafárik University, 040 11 Kosice, Slovakia
700    1_
$a Pec, Martin $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Büsselberg, Dietrich $u Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, 24144 Doha, Qatar
700    1_
$a Sadlonova, Vladimira $u Department of Microbiology and Immunology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Mojzis, Jan $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, 040 11 Košice, Slovakia
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 1 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33375383 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133010 $b ABA008
999    __
$a ok $b bmc $g 1715140 $s 1146832
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 22 $c 1 $e 20201226 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a VEGA 1/0136/19; VEGA 1/0653/19; and 1/0753/17 $p Scientific Grant Agency of the Ministry of Education of the Slovak Republic
GRA    __
$a APVV-16-0021 and APVV-16-0446 $p Slovak Research and Development Agency
GRA    __
$a ITMS2014+: 313011V455 $p Open scientific community for modern interdisciplinary research in medicine (OPENMED)
GRA    __
$a NPRP 11S-1214-170101 $p National Priorities Research Program grant (NPRP 11S-1214-170101; awarded to Professor Dr. Dietrich Büsselberg, June 2019-Current) from the Qatar National Research Fund (QNRF, a member of Qatar Foundation).
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...